INT277799

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.42
First Reported 2007
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 6
Total Number 6
Disease Relevance 3.59
Pain Relevance 0

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

nucleolus (Ms4a1)
Ms4a1 (Mus musculus)
Pain Link Frequency Relevance Heat
Pain 1 35.88 Quite Low
headache 8 14.56 Low Low
cytokine 11 11.40 Low Low
fibrosis 12 5.00 Very Low Very Low Very Low
imagery 9 5.00 Very Low Very Low Very Low
Inflammatory marker 6 5.00 Very Low Very Low Very Low
methotrexate 6 5.00 Very Low Very Low Very Low
dexamethasone 6 5.00 Very Low Very Low Very Low
Inflammation 6 5.00 Very Low Very Low Very Low
vincristine 6 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Lymphatic System Cancer 391 98.26 Very High Very High Very High
Apoptosis 21 91.48 High High
Chronic Lymphoid Leukemia 28 89.32 High High
Follicular Lymphoma 102 86.80 High High
Multiple Myeloma 16 72.80 Quite High
Death 9 71.92 Quite High
Acquired Immune Deficiency Syndrome Or Hiv Infection 8 68.40 Quite High
Htlv Types I And Ii 10 68.20 Quite High
Disease 118 68.00 Quite High
Hematologic Neoplasms 5 68.00 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
It binds specifically to the CD20 antigen with an apparent avidity 5–11 nM in vitro which is about one log greater than its parent murine antibody (IDEC Pharmaceuticals 2001).
CD20 Binding (binds) of
1) Confidence 0.42 Published 2007 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2721318 Disease Relevance 0.16 Pain Relevance 0
Radioimmunoconjugates are an attractive therapeutic option for lymphomas presumably because of the inherent sensitivity of malignant lymphoma cells to ionizing radiation coupled with the mechanism of action associated with anti-CD20 binding.
CD20 Binding (binding) of associated with lymphatic system cancer
2) Confidence 0.42 Published 2007 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2721318 Disease Relevance 0.34 Pain Relevance 0
In vitro manipulation of the extracellular epitope of the CD20 loop alters the binding to anti-CD20 monoclonal antibodies, and thus, suggests that critical mutations in CD20 may be one mechanism of resistance (Binder et al 2006).
CD20 Binding (binding) of
3) Confidence 0.31 Published 2007 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2721318 Disease Relevance 0.21 Pain Relevance 0
Antibodies targeting CD19, CD20, CD22, in combination with a toxin, CD23, CD40, CD80, and HLA-DR are being evaluated in clinical trials, and their additional benefit will be evaluated in coming years (DiJoseph et al 2004, 2006; Byrd et al 2005; Czuczman et al 2005; Foreno-Torres et al 2006).
CD20 Binding (combination) of
4) Confidence 0.21 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727901 Disease Relevance 1.21 Pain Relevance 0
Antibodies targeting CD19, CD20, CD22, in combination with a toxin, CD23, CD40, CD80, and HLA-DR are being evaluated in clinical trials, and their additional benefit will be evaluated in coming years (DiJoseph et al 2004, 2006; Byrd et al 2005; Czuczman et al 2005; Foreno-Torres et al 2006).
CD20 Binding (targeting) of
5) Confidence 0.21 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727901 Disease Relevance 1.22 Pain Relevance 0
Immunohistochemistry was performed by the means of the streptavidin-biotin-peroxidase complex method using the following primary mAbs for: CD20, ?
CD20 Binding (mAbs) of
6) Confidence 0.11 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2886845 Disease Relevance 0.45 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox